Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.

World journal of gastroenterology - 21 Nov 2016

Hlaing Naomi Khaing Than, Banerjee Debolina, Mitrani Robert, Arker Soe Htet, Win Kyaw San, Tun Nyan Lin, Thant Zaw, Win Khin Maung, Reddy K Rajender

Abstract excerpt

AIM: To investigate peg-interferon (peg-IFN) and ribavirin (RBV) therapy in Myanmar and to predict sustained virologic response (SVR). METHODS: This single-center, open-label, study was conducted in Myanmar between 2009 and 2014. A total of 288 patients infected with HCV genotypes 1, 2, 3 and 6 were treated with peg-IFN alpha-2a (180 μg/wk) or alpha-2b (50 to 100 μg as a weight-based dose) and RBV as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Developing Countries

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Costs

Share to Myanmar

Share to Polyethylene Glycols

Share to Ribavirin

Share to Serum Albumin

Share to Sustained Virologic Response

Source

Open in PubMed Open full text

Identifiers

PMID: 27920482
DOI: 10.3748/wjg.v22.i43.9613
PMCID: PMC5116605

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.PMID 27920482Read ↗

Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study.Semantic proximity Read ↗

Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.Semantic proximity Read ↗

High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmarSemantic proximity Read ↗

Intermediate hepatitis C virus (HCV) endemicity and its genotype distribution in Myanmar: A systematic review and meta-analysis.Semantic proximity Read ↗

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.Semantic proximity Read ↗

The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience.Semantic proximity Read ↗

Analysis of HCV genotypes from blood donors shows three new HCV type 6 subgroups exist in Myanmar.Semantic proximity Read ↗

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.Semantic proximity Read ↗

Peginterferon alfa-2b and ribavirin therapy in Kuwaiti patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

Distribution of hepatitis B virus genotypes in general population of Myanmar via Nation wide studySemantic proximity Read ↗

Effectiveness and safety of 3 and 5 day courses of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar.Semantic proximity Read ↗

Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.